<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03062644</url>
  </required_header>
  <id_info>
    <org_study_id>MR308-3502</org_study_id>
    <nct_id>NCT03062644</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety in a Randomised Acute Pain Study of MR308: STARDOM2.</brief_title>
  <acronym>STARDOM2</acronym>
  <official_title>A Randomized, Double-Blind, Multicenter, Placebo- and Active Comparator-Controlled Study to Evaluate Efficacy and Safety of MR308 in the Treatment of Acute Pain After Abdominal Hysterectomy Surgery Under General Anaesthesia (STARDOM2).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma Research GmbH &amp; Co KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma Research GmbH &amp; Co KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MR308-3502 study is a multicenter double-blind, randomised, placebo- and active&#xD;
      comparator-controlled study in female subjects to evaluate the efficacy and safety of MR308&#xD;
      with acute pain after TAH or STAH (total or subtotal abdominal hysterectomy).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter double-blind, randomised, placebo- and active comparator-controlled&#xD;
      study in female subjects to evaluate the efficacy and safety of MR308 with acute pain after&#xD;
      total or subtotal abdominal hysterectomy (TAH or STAH).&#xD;
&#xD;
      The screening Visit (Visit 1) can take place up to 28 days before the planned TAH or STAH.&#xD;
      The surgery will be performed at Visit 2. Visit 2 consists of three different sections, a&#xD;
      part before the surgery, the surgery and post surgery. On the next Day (Visit 3) subjects&#xD;
      will qualify for further participation by regular measurements of their pain. Subjects&#xD;
      meeting all eligibility criteria, such as defined pain levels, will be randomised to one of&#xD;
      six treatment groups and be given IMPs for 120h. Subjects who will not be randomised are&#xD;
      screen failures and will be given standard care as per local practice.&#xD;
&#xD;
      Visits 4, 5, 6 ,7 and 8, one to five days after randomisation will be performed to record&#xD;
      efficacy and safety parameters.&#xD;
&#xD;
      The last dose of IMP should be taken by the subject about 120h after the initial dose and&#xD;
      before Visit 8 (Completion/Discontinuation Visit) is performed.&#xD;
&#xD;
      The Adverse Event (AE) Follow up Visit (Visit 9) is the last study visit and should not be&#xD;
      done earlier than seven days after the subject's last dose of IMP. It can be performed by&#xD;
      telephone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 5, 2017</start_date>
  <completion_date type="Actual">June 29, 2018</completion_date>
  <primary_completion_date type="Actual">June 29, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of MR308 doses in the treatment of moderate to severe acute pain, based on the Sum of Pain Intensity Differences (SPID) from 0-4 hours.</measure>
    <time_frame>0-4 hours</time_frame>
    <description>The primary efficacy endpoint is the Sum of Pain Intensity Differences over 0-4 hours (SPID4). SPID4 is derived as the weighted Sum of Pain Intensity Differences (baseline pain - current pain), measured at different time points via the PI-VAS. Time between two consecutive measurements will be used for weighting. Larger values indicate larger pain relief.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1138</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>MR308 100 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tramadol/Celecoxib)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MR308 150 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tramadol/Celecoxib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MR308 200 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tramadol/Celecoxib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tramadol 100 mg qid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tramadol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib 100 mg bid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Celecoxib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MR308</intervention_name>
    <description>two times daily; Mode of Administration:oral</description>
    <arm_group_label>MR308 100 mg bid</arm_group_label>
    <arm_group_label>MR308 150 mg bid</arm_group_label>
    <arm_group_label>MR308 200 mg bid</arm_group_label>
    <other_name>Tramadol/Celecoxib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MR308</intervention_name>
    <description>four times daily; Mode of Administration:oral</description>
    <arm_group_label>Tramadol 100 mg qid</arm_group_label>
    <other_name>Tramadol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MR308</intervention_name>
    <description>two times daily; Mode of Administration:oral</description>
    <arm_group_label>Celecoxib 100 mg bid</arm_group_label>
    <other_name>Celecoxib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MR308</intervention_name>
    <description>given four times daily to maintain the blind; Mode of Administration:oral</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female subjects ≥ 18 years on the day of consent.&#xD;
&#xD;
          2. Willing and able to provide written informed consent for this study.&#xD;
&#xD;
          3. Subjects are scheduled to have a total or subtotal abdominal hysterectomy under&#xD;
             general anasethesia via a Pfannenstiel incision.&#xD;
&#xD;
          4. The elective procedure (total or subtotal hysterectomy with or without&#xD;
             salpingo-oophorectomy) must be for benign conditions within 28 days of screening.&#xD;
             Subjects with stage 0 carcinoma in situ of cervix, endometrial hyperplasia or&#xD;
             clinically staged 1A or 1B endometrial cancer are allowed to participate.&#xD;
&#xD;
          5. American Society Anaesthesiology physical status of I or II.&#xD;
&#xD;
          6. If a female is of child-bearing potential, she must be using highly effective methods&#xD;
             of contraception throughout the study, not breastfeeding, and have negative pregnancy&#xD;
             tests prior to receiving IMP. A highly effective method of birth control is defined as&#xD;
             one which results in a low failure rate (i.e. less than 1% per year) when used&#xD;
             consistently and correctly such as sterilisation, implants, injectables, combined oral&#xD;
             contraceptives, some IUDs (Intrauterine Device, hormonal), sexual abstinence or&#xD;
             vasectomised partner).&#xD;
&#xD;
          7. Good general health as judged by Investigators on the basis of medical history and&#xD;
             physical examination.&#xD;
&#xD;
          8. Willingness to comply with the study procedures and requirements.&#xD;
&#xD;
        Additional Inclusion Criteria after Surgery:&#xD;
&#xD;
          1. Abdominal hysterectomy completed without any immediate complication.&#xD;
&#xD;
          2. Tolerating oral fluids, no uncontrolled nausea/vomiting and ready to take oral&#xD;
             analgesia.&#xD;
&#xD;
          3. The subject is alert and calm, spontaneously pays attention to caregiver, e.g. RASS =&#xD;
             0 (Sessler et al., 2002 &amp; Ely et al., 2003).&#xD;
&#xD;
          4. Subjects will be capable to sit up from supine, stand up from a sitting position and&#xD;
             walk 10 meters without assistance in the morning of the day following surgery.&#xD;
&#xD;
          5. Subjects with moderate or severe pain (qualifying PI-VAS score ≥ 45mm and &lt; 70mm or ≥&#xD;
             70mm and ≤ 90mm) as a result of a surgical procedure (abdominal hysterectomy) under&#xD;
             general anaesthesia. This must be measured within a maximum of 24 hours after leaving&#xD;
             the recovery room and subjects can only be randomised on the day after surgery, after&#xD;
             cessation of the post-operative analgesia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any abnormal laboratory value that is clinically significant in the opinion of&#xD;
             Investigator that would compromise the safety of the subject in the study.&#xD;
&#xD;
          2. Any recent history of frequent nausea or vomiting, dizziness within the last 3 months&#xD;
             regardless of etiology.&#xD;
&#xD;
          3. Subjects having any medical condition or treatment that is either a warning or&#xD;
             contraindication as per the SmPC of tramadol (e.g. selective serotonin reuptake&#xD;
             inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic&#xD;
             antidepressants, MAO inhibitors (within 14 days before taking IMP), antipsychotics,&#xD;
             anticonvulsant and other seizure threshold-lowering medicinal products), celecoxib&#xD;
             (e.g. increased risk of post-operative bleeding, active peptic ulceration, GI bleeding&#xD;
             or inflammatory bowel disease) or paracetamol.&#xD;
&#xD;
          4. Known sensitivity and/or contraindication to tramadol, celecoxib, paracetamol,&#xD;
             sulfonamides, opioids, NSAIDS, COX-2 inhibitors, or related compounds or formulation&#xD;
             excipients as well as severe hypersensitivity reactions (e.g. anaphylactic shock,&#xD;
             bronchospasm, angioedema) to any drugs.&#xD;
&#xD;
          5. Subjects who are known to have had inadequate pain relief from paracetamol, tramadol&#xD;
             or celecoxib.&#xD;
&#xD;
          6. Subjects requiring any medication which is prohibited as per section prohibited&#xD;
             medication.&#xD;
&#xD;
          7. Subjects who are in the Investigator's opinion considered at increased risk of&#xD;
             operative (those associated with the surgical procedure and general anaesthesia) and&#xD;
             post-operative complications, e.g. excessive post-operative bleeding, infection.&#xD;
&#xD;
          8. Any history of drug or alcohol abuse, misuse, physical or psychological dependence,&#xD;
             mood changes, sleep disturbance and functional capacity which have an impact on pain&#xD;
             perception.&#xD;
&#xD;
          9. Significant neurological or psychiatric disorders including mental instability&#xD;
             (unrelated to the pain) that could interfere with pain assessment; other pre-existing&#xD;
             or new non-abdominal/pelvic pain that might impair the assessment of the nociceptive&#xD;
             pain.&#xD;
&#xD;
         10. Any medical history of significant and/or inadequately controlled cardiovascular&#xD;
             (uncontrolled high blood pressure, high risk of cardiovascular events, severe heart&#xD;
             failure), pulmonary, hematologic, (including coagulopathy/bleeding disorders),&#xD;
             neurological (e.g. subjects with epilepsy or those susceptible to seizures), liver&#xD;
             disease (e.g. severe hepatic impairment), kidney disease (e.g. serum creatinine level&#xD;
             greater than 1.5 times the upper limit of normal, impaired renal function in subjects&#xD;
             taking diuretics, ACE-inhibitors, or angiotensin II antagonists), endocrine,&#xD;
             immunologic, dermatologic painful conditions or any other conditions that may&#xD;
             compromise the ability of the subject to participate in the study or might interfere&#xD;
             with drug absorption, distribution, metabolism or excretion.&#xD;
&#xD;
         11. Previous randomisation in this study.&#xD;
&#xD;
         12. Subjects who participated in a clinical research study involving a new chemical entity&#xD;
             or an experimental drug within 30 days of study entry (defined as the start of the&#xD;
             Screening Period).&#xD;
&#xD;
         13. Subjects who were treated regularly with opioid analgesic or NSAIDs within 30 days&#xD;
             prior to screening or who have received a long-acting NSAID within three days prior to&#xD;
             the start of the surgery.&#xD;
&#xD;
         14. Subjects who are incapable of complying with the protocol.&#xD;
&#xD;
         15. Epidural or spinal anaesthesia or infiltration of the wound with an infusion of a&#xD;
             local anaesthetic agent is not allowed. A single perioperative dose is allowed.&#xD;
&#xD;
         16. History or ongoing chronic pelvic inflammatory disease or painful endometriosis.&#xD;
&#xD;
         17. History of advanced gynaecological cancers.&#xD;
&#xD;
        Additional Exclusion Criteria after Surgery:&#xD;
&#xD;
          1. Serious complication during surgery and up to randomisation, including:&#xD;
&#xD;
               -  Post-operative primary and secondary bleed that cannot be controlled.&#xD;
&#xD;
               -  Subjects who have not had the abdominal hysterectomy surgery completed as&#xD;
                  planned.&#xD;
&#xD;
          2. If in the Investigator's opinion, there are any factors that may affect compliance&#xD;
             with the protocol.&#xD;
&#xD;
          3. Subject clinical need for antiemetics (apart from standard perioperative practice as&#xD;
             defined in the protocol) or any other medication which is prohibited as per section&#xD;
             prohibited medication.&#xD;
&#xD;
          4. Subjects who have received any analgesic medication other than perioperative analgesia&#xD;
             as described in the protocol.&#xD;
&#xD;
          5. Any concerns that renal function has deteriorated, e.g. a laboratory parameter,&#xD;
             profound hypotension, poor urine output or excessive bleeding during surgery.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Minsk City Gynecology Hospital Department of Gynecology</name>
      <address>
        <city>Minsk</city>
        <zip>220007</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Multiprofile Hospital for Active Treatment - Doverie&quot; AD, Sofia Department of Gynecology</name>
      <address>
        <city>Sofia</city>
        <zip>1632</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria Hospital - London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bajcsy-Zsilinszky Korhaz Szuleszet-Nogyogyaszati Osztaly</name>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vidzeme Hospital Department of Gynecology and Obstetrics</name>
      <address>
        <city>Valmiera</city>
        <zip>4201</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital im. Św. Ojca Pio w Przemyślu Oddział Ginekologii i Położnictwa</name>
      <address>
        <city>Przemysl</city>
        <zip>37-700</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution National Medical-Surgical Centre named after N.I. Pirogov of the Ministry of Health of the Russian Federation Anesthesiology</name>
      <address>
        <city>Moscow</city>
        <zip>105203</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol Anestesia y Reanimación</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Lithuania</country>
    <country>Romania</country>
    <country>Slovakia</country>
  </removed_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>February 20, 2017</study_first_submitted>
  <study_first_submitted_qc>February 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>September 19, 2018</last_update_submitted>
  <last_update_submitted_qc>September 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open Total or Subtotal Abdominal Hysterectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

